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Eﬀ ects of anastrozole on cognitive performance in 
postmenopausal women: a randomised, double-blind 
chemoprevention trial (IBIS II)
Valerie A Jenkins, Laurence M Ambroisine, Louise Atkins, Jack Cuzick, Anthony Howell, Lesley J Fallowﬁ eld
Summary
Background Mild cognitive impairments have been recorded in cross-sectional studies of women with breast cancer 
receiving endocrine treatment. More comprehensive studies were warranted because aromatase inhibitors are being 
used increasingly in both chemoprevention and adjuvant settings. We report ﬁ ndings from the cognitive subprotocol 
of the International Breast Intervention Study (IBIS II), a double-blind placebo-controlled trial of anastrozole in 
postmenopausal women at high risk of developing breast cancer. We aimed to study and compare the eﬀ ect of 
anastrozole versus placebo on memory and attention in these women. 
Methods Between Jan 3, 2003, and Dec 21, 2005, participants were recruited into the cognitive subprotocol from ﬁ ve 
UK centres. Cognitive assessments were done before randomisation, at 6 months, and at 24 months. 227 of 249 women 
approached completed a comprehensive set of standardised cognitive tasks at baseline and were randomly assigned 
to receive anastrozole (1 mg/day for 5 years) or placebo. Psychological morbidity, endocrine symptoms, and self-
reported cognitive complaints were also measured. The main outcomes were cognitive task scores at baseline, 
6 months, and 24 months. Analyses were done by intention to treat. This study is registered as an International 
Standard Randomised Controlled Trial, number ISRCTN31488319.
Findings 111 women were assigned to anastrozole and 116 women to placebo. At 6 months, ten women in each group 
were excluded from analysis, leaving a total of 207 of 227 (91%) women available for further assessments. At 
24 months, 24 women were excluded from the anastrozole group and 32 from the placebo group, leaving 151 of 
227 (67%) women. We did not note any signiﬁ cant diﬀ erences between the groups for any of the cognitive tasks. By 
6 months, 13 women in both groups reported changes to their memory and this had decreased to ﬁ ve women in the 
placebo group and three women in the anastrozole group by the 24-month assessment. Signiﬁ cantly more women in 
the anastrozole group complained of hot ﬂ ushes at 24 months (23 of 76 [30%] vs 11 of 73 [15%], p=0·032, not corrected 
for multiple comparison), but this was the only diﬀ erence in reported endocrine symptoms.
Interpretation These ﬁ ndings show little or no impairment of cognitive performance with the use of anastrozole 
compared with placebo in postmenopausal women at high risk of developing breast cancer who were able to tolerate 
endocrine-related side-eﬀ ects. Future studies assessing cognition should be done within randomised trials with 
baseline assessments to ascertain the true extent of the putative eﬀ ects that treatments for breast cancer might have 
on memory and attention.
Funding Cancer Research UK, London, UK (grant numbers C6280/A3162 and C6280/A6764). 
Introduction
Breast cancer is the most common cancer in the UK, 
with more than 44 000 women diagnosed in 2004.1 
Although mortality is declining, incidence continues to 
increase, and therefore, prevention is an important aim. 
Four prevention trials that used tamoxifen versus a 
placebo in high-risk women have suggested an overall 
decrease of breast cancer of 38%,2,3 and a considerable 
beneﬁ cial carry-over eﬀ ect of tamoxifen has been 
reported.4 Tamoxifen has a good therapeutic ratio in 
premenopausal women, but this is less true in 
postmenopausal women.5 In many adjuvant trials, 
aromatase inhibitors have been shown to be better than 
tamoxifen in preventing relapse, but also decrease the 
incidence of contralateral breast cancer by about 50% 
compared with tamoxifen.6 These data provided the 
rationale for prevention trials that used aromatase 
inhibitors, such as the International Breast Intervention 
(prevention) Study (IBIS II), which compares 5 years of 
anastrozole treatment (1 mg/day) with placebo in 
postmenopausal women at increased risk of breast 
cancer. 
Although prevention of breast cancer is a worthy goal, 
this needs to be achieved with as little iatrogenic harm as 
possible to be acceptable. The IBIS I trial,4 a double-blind 
placebo-controlled randomised trial of tamoxifen, 
20 mg/day for 5 years, in women aged 35–70 years 
(median age 46 years) who were at increased risk of 
breast cancer, showed beneﬁ ts in the prevention of breast 
cancer, but these were partially oﬀ set by side-eﬀ ects, 
especially thromboembolic events. Depletion of oestrogen 
with aromatase inhibitors in otherwise healthy women 
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could prove unacceptable in terms of an increase in 
menopausal-type symptoms and might have detrimental 
eﬀ ects on cognitive function. Studies assessing the eﬀ ect 
of endocrine treatments alone on cognition in women at 
risk of or treated for breast cancer are rare.7,8 Most 
published studies tried unsuccessfully to separate the 
potential eﬀ ects of endocrine treatment in patients with 
breast cancer who had already received chemo therapy.9 
The topic is confounded by previous use of chemo-
therapy, inappropriate sample sizes, and other method-
ological issues.10
Because of the very low oestradiol concentrations in 
women who take aromatase inhibitors, we did a 
preliminary cross-sectional study of cognitive function 
in the anastrozole, tamoxifen, alone or combined (ATAC) 
adjuvant trial. This trial was an international adjuvant 
breast cancer trial of endocrine treatments for 
postmenopausal women. We assessed memory and 
attention in women (n=94) who had been in the ATAC 
trial for a median of 36 months, and who had not 
received chemotherapy. Patients’ data were compared 
with those from an age-matched control group.7 Findings 
showed a signiﬁ cantly poorer performance on tasks of 
verbal memory and processing speed in the patients 
with breast cancer. However, the numbers of patients 
allo cated to the diﬀ erent treatment arms were too small 
to do any between-group analyses to establish whether 
tamoxifen or anastrozole, or the combination, was 
implicated. Also no pre-treatment baseline assessment 
of the patients’ performance was done to be able to 
establish whether or not the eﬀ ect was a result of 
endocrine treatment. 
Bender and colleagues8 assessed cognitive function, 
depression, anxiety, and fatigue in a small group of 
postmenopausal women with early-stage breast cancer 
who were treated with tamoxifen or anastrozole for at 
least 3 months. The researchers reported that women 
who received anastrozole (n=15) had poorer verbal and 
visual learning and memory than those who received 
tamoxifen (n=16). However, the sample size was small 
and no pre-treatment data were available. The IBIS II 
trial provided the opportunity to assess cognitive function 
in a prospective, longitudinal, randomised, placebo-
controlled clinical trial. 
Methods
Patients
Between Jan 3, 2003, and Dec 21, 2005, postmenopausal 
women at increased risk of developing breast cancer 
(determined from family history [ﬁ rst-degree relatives 
with breast cancer at age <50 years or two or more 
second-degree relatives with breast cancer]; previous 
benign disease with evidence of proliferation or atypia; 
mammographic dysplasia; or nulliparity plus any ﬁ rst-
degree family history) were recruited into the cognitive 
subprotocol from ﬁ ve UK centres (Royal Bolton Hospital, 
Bolton; Breast Care Centre, Frenchay Hospital, Bristol; 
Department of Surgery, University Hospital of Wales, 
Cardiﬀ ; Nightingale Centre and Genesis Prevention 
Centre, University Hospital of South Manchester, 
Manchester; and Royal Marsden Hospital, London). All 
women gave written consent to participate in the IBIS II 
(prevention) trial. The primary endpoint of the prevention 
trial was to ascertain if anastrozole (1 mg/day for 5 years; 
AstraZeneca, Macclesﬁ eld, UK) was eﬀ ective in pre-
venting invasive and non-invasive breast cancer in 
postmenopausal women at increased risk of the disease. 
The secondary endpoints were to study the role of 
anastrozole in preventing oestrogen-receptor-positive 
breast cancer, breast-cancer mortality, assess the eﬀ ect of 
anastrozole on other cancers, cardiovascular disease, 
fracture rates, and non-breast-cancer deaths. The main 
clinical trial is still open to recruitment and ﬁ ndings for 
the primary endpoint have not been reported. The 
cognitive study is a separate protocol from the main 
clinical trial.
Women were invited to join the cognitive subprotocol 
by the clinician, research nurse, or researcher from 
Cancer Research UK Psychosocial Oncology Group 
before randomisation. Randomisation was blind and 
occurred automatically at Cancer Research UK via the 
internet by use of speciﬁ cally written software for the 
trial. The randomisation tables were drawn up stratiﬁ ed 
by country and the randomisation was balanced in blocks, 
with sizes randomly selected to be 6, 8, or 10. Inclusion 
criteria for the cognitive study were ability to speak and 
read English, and being a participant in the IBIS II trial. 
116 women assigned to placebo 111 women assigned to anastrozole
227 women randomised at baseline assessment
10 women excluded
      2 intolerable endocrine symptoms
      3 did not like cognitive tests
      2 family problems
      2 forgot to take medication
      1 lost to follow-up
10 women excluded
      5 intolerable endocrine symptoms
      2 did not like cognitive tests
      2 family problems
      1 lost to follow-up
32 women excluded
      15 intolerable endocrine symptoms
        4 did not like cognitive tests
        5 other medical condition
        2 other cancer diagnosis
        6 lost to follow-up
24 women excluded
      12 intolerable endocrine symptoms
        3 did not like cognitive tests
        1 family problems
        2 other cancer diagnosis
        1 same risk as general population      
        5 lost to follow-up
106 available for 6-month 
         assessment
101 available for 6-month 
         assessment
   74 available for 24-month 
         assessment
   77 available for 24-month 
         assessment
Figure 1: Study proﬁ le
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Exclusion criteria for the cognitive study included those 
with a previous history of stroke, dementia, degenerative 
disease, and alcohol or drug abuse. 
The cognitive study had full ethical approval and all 
participants gave written informed consent. 
Assessments
The standardised cognitive assessments and interviews 
were done by one of four experienced psychologists (VAJ, 
LA, HH, BM) trained in the administration of neuro-
psychological tests. The assessments (webpanel) were 
done at baseline, 6 months, and 24 months, apart from 
the measure of intelligence, which was done only once 
at baseline. The cognitive test assessed several broad 
areas and comprised nine objective tasks (yielding 
17 measures for analysis) covering the functional areas of 
verbal and visual memory with both immediate and 
delayed recall, working memory, processing speed 
and executive function. The tests were administered in 
the same order and recommended alternative versions of 
tasks were used where appropriate to decrease the chance 
of practice eﬀ ects occurring. Where alternative versions 
of tasks were available these were presented in a counter-
balanced order between participants across the three 
timepoints, eg, word ﬂ uency, logical memory, complex 
ﬁ gure, and word lists. These standardised neuro-
psychological tasks are sensitive and have shown changes 
between patient groups in previous breast-cancer studies 
described elsewhere.7,11
Self-reported measures 
At each timepoint, participants also completed the 
General Health Questionnaire 12 (GHQ12),12 the 
Broadbent cognitive failures questionnaire (CFQ),13 and 
the endocrine symptoms subscale (ES).14 The GHQ12 is a 
12-item general health measure designed to screen for 
probable, non-psychotic psychiatric disorder in com-
munity and medical settings. It is an important factor to 
measure as self-reported memory complaints correlate 
strongly with increased anxiety.15 The CFQ was developed 
to assess explicitly propensity for committing a cognitive 
failure related to perception, memory, and motor function. 
It comprises 25 questions relating to lapses in attention 
in everyday life, and responses are ranged as: 0=never, 
1=very rarely, 2=occasionally, 3=quite often, 4=very often. 
Scores were summed to obtain an overall CFQ score. 
Higher scores suggest increased forgetfulness. Also, as 
part of a structured interview, patients were asked at 
6 months and 24 months whether they had noticed any 
changes in their memory or concentration and at 
24 months about adherence to trial drugs. 
Statistical analyses
All statistical analyses were done by use of Stata software, 
version 9.2.
Psychiatric morbidity, self-reports of memory changes, 
concentration changes, and scores from the cognitive 
failures questionnaire were compared at each timepoint 
among treatment groups by use of Pearson’s χ2 test (or 
Fisher’s exact test when appropriate) for categorical 
variables and Wilcoxon rank-sum test for interval vari-
ables. Baseline cognitive performance on each measure 
was analysed by use of linear least squares multiple 
regressions, and the residuals were checked for normality. 
The independent variables were treatment group, age, 
All participants 
(n=227)
Participants in main 
analysis (n=207)
Mean age, years (SD) 57 (5) 57 (5)
Partner, n (%) 183 (81) 166 (80)
Mean full-scale intelligence 
quotient (SD)
113 (10) 113 (10)
HRT use before trial, n (%)* 
Never used 102 (45) 91 (44)
<6 months 13 (6) 10 (5)
6–11 months 19 (8) 19 (9)
≥12 months 91 (40) 85 (41)
GHQ12 score ≥4, n (%) 44 (19) 44 (21)
Mean self-reported Broadbent 
cognitive failures, n (SD)
42 (12) 42 (12)
*Data for two patients in both groups are missing. 
Table 1: Baseline characteristics of all 227 participants and the 207 





GHQ12 score ≥4, n (%)
Baseline 24 (23) 20 (20)
6 months 27 (25) 24 (24)
24 months* 23 (31) 17 (22)
Drug holidays advised, n (%)
By 6 months 1 (<1) 5 (5)
From 6 months to 24 months* 0 1 (1)
Drug holiday initiated by patient, n (%)
By 6 months 3 (3) 4 (4)
From 6 months to 24 months* 1 (1) 3 (4)
Self-reported memory changes, n (%)
By 6 months 13 (12) 13 (13)
From 6 months to 24 months* 5 (7) 3 (4)
Self-reported concentration changes, n (%)
By 6 months 12 (11) 7 (7)
From 6 months to 24 months* 2 (3) 2 (3)
Mean self-reported Broadbent cognitive failures, n (SD)
Baseline 40 (11) 43 (12)
6 months 40 (13) 43 (12)
24 months* 39 (12) 41 (13)
*Restricted to the 151 participants who completed all three assessments (n=74 for 
placebo group and n=77 for anastrozole group).
Table 2: Details of the 207 participants in the main analysis
See Online for webpanel
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intelligence quotient (IQ), psychological distress (GHQ12), 
and previous hormone replacement therapy (HRT) use.
After checking that the 17 objective cognitive measures 
had similar values at 6 months and 24 months by use of 
the Wilcoxon signed ranks test, a mean of the two values 
was calculated. If one value was missing, the other was 
imputed as the mean. For each patient and for each 
cognitive measure, the change from baseline was 
calculated as the diﬀ erence between the mean value at 
6 months and 24 months and the baseline value. To test 
for a signiﬁ cant change from baseline, the mean change 
from baseline of each measure was compared to 0 by use 
of the Wilcoxon signed ranks test. The diﬀ erence between 
treatment groups was tested by comparing the mean 
changes from baseline between the placebo and 
anastrozole groups by use of the Wilcoxon rank-sum test.
Such group comparisons can mask impairment in 
subgroups of the population. Therefore, to study 
performance for an individual woman, we used the 
reliable change index (RCI) with a correction for observed 
practice eﬀ ects on each measure.16 By using this method, 
an RCI was calculated for each measure by use of the 
baseline and 6-month, and the baseline and 24-month 
data of the placebo participants. For each participant, if 
the score calculated fell outside the RC interval, a 
signiﬁ cant change in performance was considered to 
have occurred. Statistical tests were two-sided and 
performed at 0·05 signiﬁ cance level. The analyses were 
done by intention to treat. This study is registered as an 
International Standard Randomised Controlled Trial, 
number ISRCTN31488319.
Role of the funding source
Cancer Research UK funded the cognitive subprotocol 
(grant numbers C6280/A3162 and C6280/A6764) and 
had no involvement in the study design, collection, 
analysis, or interpretation of the data or in the writing of 
the report. VAJ, LMA, LA, and JC had access to the raw 
data. The corresponding author had ﬁ nal responsibility 
to submit for publication.
Results
227 of 249 (91%) women approached agreed to participate 
in the cognitive function subprotocol, 207 (91%) of whom 
completed both the baseline and 6-month assessments, 
and of those interviewed at 6 months, 151 (67%) also 
completed a 24-month assessment (ﬁ gure 1). 76 women 
failed to complete all three cognitive assessments. 
Reasons for non-completion at 6 months and 24 months 
are shown in ﬁ gure 1. We did not note a signiﬁ cant 
diﬀ erence at baseline between those who were and those 
who were not excluded in terms of age, IQ, previous HRT 
use or GHQ12 scores (data not shown). 
However, 34 of the 76 (45%) women cited endocrine 
symptoms as the main reason for withdrawing, seven 
before the 6-month assessment (ﬁ ve anastrozole, two 
placebo) and 27 before the 24-month assessment 
(12 anastrozole, 15 placebo).
The baseline characteristics of all participants and of 
those included in the main analysis are shown in table 1. 
The characteristics were similar across treatments (data 
not shown), with the exception of HRT use, which was 
greater in the placebo group (77/116 [66%] vs 46/109 [42%] 
for all participants, and 72/106 [68%] vs 42/99 [42%] for the 
participants in main analysis). The psychological 
characteristics of the groups were similar at trial entry 
with 20 of 101 (20%) women in the anastrozole group and 
24 of 106 (23%) women in the placebo group scoring above 
the threshold on the GHQ12 (table 2). These proportions 
were only slightly higher than the 18% of above threshold 
scores recorded in healthy populations.17 There was also 
no signiﬁ cant diﬀ erence on the baseline characteristics 
and baseline scores between those who did and did not 
complete the 24-month assessment (data not shown).
Treatment group was unrelated to cognitive per-
formance at baseline on any of the objective measures 
Placebo
AnastrozoleAuditory verbal learning
   Immediate recall
   Total recall 1–5
   Delayed recall 7
Logical memory
   Immediate recall
   Delayed recall
Complex ﬁgure
   Immediate
   Delayed
Letter cancellation
   Eﬃciency
Letter number sequencing
Spatial span
   Forwards
   Backwards
   Total
Digit span
   Forward
   Backwards
   Total
Executive function
   Stroop
Total verbal ﬂuency
–1·5 1·50·5–0·5 3·0  –2·0 1·00–1·0 2·52·0
Figure 2: Mean changes and 95% CIs from baseline for each cognitive task by treatment group
Articles
www.thelancet.com/oncology   Vol 9   October 2008 957
independent of age, intelligence, menopausal status, 
CFQ, and GHQ12 scores. Age and intelligence independ-
ently predicted baseline cognitive performance (data not 
shown). To calculate the mean change from baseline 
when there were missing values at baseline, the baseline 
values were imputed by use of a linear regression analysis 
of the measure on age and intelligence.
The potential eﬀ ect of HRT use on cognitive function 
at baseline was assessed for both groups combined. 
There was a signiﬁ cant main eﬀ ect of HRT use (never vs 
recent or past) on four measures at baseline. Higher 
mean scores for logical memory immediate, logical 
memory delayed, letter number sequencing, and 
improved performance on a task of executive function 
were in favour of the non-HRT users (non-HRT vs HRT, 
mean [SD]: 14·55 [4·00] vs 12·94 [4·21], p=0·007; 13·10 
[4·14] vs 11·81 [4·10], p=0·020; 11·78 [2·33] vs 10·67 [2·47], 
p=0·003; 42·59 [8·76] vs 38·33 [8·20], p<0·001, not 
corrected for multiple comparison, respectively).
Figure 2 shows the mean change from baseline with 
95% CIs for each task by treatment group. Table 3 shows 
the mean scores and standard deviations for each task by 
treatment group and at the three timepoints. There were 
no signiﬁ cant diﬀ erences between the anastrozole and 
placebo groups for any of the objective cognitive tasks. 
For both groups combined, there was a signiﬁ cant eﬀ ect 
of time for two tasks having an increased value from 
baseline (mean change from baseline [SE]: complex 
ﬁ gure immediate recall 1·24 [0·36]; complex ﬁ gure 
delayed recall 1·33 [0·33]; table 4). When the analysis was 
restricted to the baseline and 6-month data, there were 
no signiﬁ cant diﬀ erences between the anastrozole and 
placebo groups, and no eﬀ ect of time for any of the 






















Auditory verbal learning 
Immediate recall 1* 5·89 (1·74) 5·93 (1·65) 5·77 (1·70) 5·99 (1·71) 5·67 (1·26) 5·81 (1·55) 5·67 (1·65) 5·71 (1·58) 5·54 (1·61) 5·80 (1·65)
Total recall 1–5* 46·62 (8·67) 47·72 (8·43) 46·08 (9·08) 48·08 (8·77) 47·20 (8·07) 45·59 (8·54) 46·04 (9·09) 45·22 (8·77) 45·66 (8·84) 46·60 (8·72)
Delayed recall 7*†‡ 8·69 (3·22) 9·14 (3·00) 8·64 (3·27) 9·23 (3·15) 8·89 (3·32) 8·77 (3·13) 9·13 (3·27) 8·87 (3·10) 9·26  (3·08) 8·79 (3·24)
Logical memory
Immediate recall 14·04 (4·20) 14·20 (4·21) 14·40 (4·36) 14·53 (4·48) 14·30 (4·45) 13·19 (4·14) 13·96 (4·21) 12·80 (4·15) 13·95 (4·12) 13·13 (3·76)
Delayed recall¶¶¶ 12·69 (4·12) 13·06 (4·14) 13·03 (4·19) 13·34 (4·26) 12·77 (4·10) 12·02 (4·21) 12·34 (4·71) 11·66 (4·17) 12·23 (4·78) 11·91 (3·63)
Complex ﬁ gure
Immediate recall§¶|| 22·35 (6·16) 23·42 (6·36) 22·66 (6·07) 23·31 (6·39) 24·39 (6·10) 22·29 (6·58) 22·82 (6·30) 22·66 (6·68) 22·64 (6·51)  23·93 (6·57)
 Delayed recall‡§¶ 22·35 (5·81) 23·37 (6·10) 22·77 (5·68) 23·39 (6·19) 24·41 (6·12) 22·07 (6·51) 22·75 (5·87) 22·32 (6·64) 22·56 (6·12) 23·83 (6·89)
Letter number cancellation
Eﬃ  ciency*,** 41·26 (8·13) 42·07 (7·90) 42·02 (8·21) 42·57 (8·38) 42·06 (7·92) 40·78 (7·24) 42·30 (7·79) 39·98 (7·18) 41·86 (7·64) 40·24 (7·16)
Letter number 
sequencing††
11·10 (2·47) 10·84 (2·50) 10·90 (2·49) 10·90 (2·61) 10·61 (2·18) 11·08 (2·56) 10·85 (2·82) 10·84 (2·54) 10·56 (2·74) 10·09 (2·32)
Spatial span 
Forwards*‡,‡‡ 7·52 (1·76) 7·42  (1·82) 7·67 (1·66) 7·40 (1·70) 7·42 (1·49) 7·37 (1·88) 7·16 (1·78) 7·49 (1·84) 7·21 (1·76) 7·28 (1·72)
Backwards*‡,‡‡ 6·94 (1·41) 7·06 (1·71) 6·97 (1·38) 7·11 (1·65) 6·89 (1·51) 6·80 (1·52) 6·78 (1·55) 6·71 (1·54) 6·72 (1·57) 6·54 (1·59)
Total*‡†† 14·47 (2·78) 14·48 (3·03) 14·64 (2·60) 14·51 (2·80) 14·31 (2·35) 14·17 (2·80) 13·94 (2·80) 14·21 (2·74) 13·93 (2·74) 13·81 (2·82)
Digit span
Forwards§§¶¶|||| 10·21 (2·18) 10·56 (2·07) 10·12 (2·22) 10·63 (2·14) 9·90 (2·08) 10·46 (2·10) 10·36 (1·93) 10·36 (2·13) 10·31 (1·93) 10·19 (2·19)
 Backwards¶¶||||*** 7·41 (2·15) 7·04 (2·16) 7·26 (2·01) 7·03 (2·03) 6·45 (1·86) 7·09 (2·40) 6·75 (2·56) 7·06 (2·35) 6·74 (2·53) 6·80 (2·26)
Total¶¶||||*** 17·58 (3·73) 17·70 (3·84) 17·36 (3·64) 17·81 (3·89) 16·36 (3·40) 17·47 (3·89) 17·11 (3·88) 17·32 (3·89) 17·05 (3·85) 16·99 (3·95)
Executive function
Stroop†,†††‡‡‡ 40·51 (8·76) 40·73 (8·57) 41·19 (9·08) 41·30 (8·93) 41·44 (9·49) 39·69 (9·02) 40·06 (8·17) 39·25 (8·68) 40·09 (8·06) 40·08 (7·79)
Total verbal ﬂ uency§§§ 44·23 (11·06) 44·56 (12·27) 45·24 (11·29) 44·96 (13·00) 43·39 (12·68) 44·40 (13·70) 45·04 (13·26) 44·95 (14·30) 45·23 (14·09) 44·29 (13·69)
Missing data are given at baseline and 6 months for 207 participants and at 24 months for 151 participants. *At baseline, data missing from 1 placebo patient. †At 6 months, data missing from 1 anastrozole 
patient. ‡At 24 months, data missing from 1 placebo patient and 1 anastrozole patient. §At baseline, data missing from 4 placebo patients. ¶At 6 months, data missing from 1 placebo patient. ||At 24 months, 
data missing from 1 placebo patient. **At 6 months, data missing from 2 placebo patients and 1 anastrozole patient. ††At baseline, data missing from 1 placebo patient and 2 anastrozole patients; at 6 months, 
data missing from 2 placebo patients and 2 anastrozole patients; at 24 months, data missing from 2 placebo patients and 1 anastrozole patient. ‡‡At 6 months, data missing from 1 placebo patient and 
1 anastrozole patient. §§At baseline, data missing from 1 anastrozole patient. ¶¶At 6 months, data missing from 2 anastrozole patients. ||||At 24 months, data missing from 1 placebo patient and 2 anastrozole 
patients. ***At baseline, data missing from 1 placebo patient and 1 anastrozole patient. †††At baseline, data missing from 2 placebo patients. ‡‡‡At 24 months, data missing from 2 anastrozole patients. §§§At 
baseline, data missing from 2 placebo patients and 2 anastrozole patients; at 6 months, data missing from 3 placebo patients and 3 anastrozole patients; at 24 months, data missing from 3 placebo patients and 
2 anastrozole patients. ¶¶¶At baseline data missing from 2 anastrozole patients; at 24-months data missing from 1 anastrozole patient.
Table 3: Mean scores (SD) by treatment group for each task at baseline, 6 months, and 24 months for the 207 participants in the main analysis (n=106 for placebo group, n=101 for 
anastrozole group) and the 151 participants who completed all three assessments (n=74 for placebo group, n=77 for anastrozole group)
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We also did a principal components analysis to ﬁ nd a 
smaller set of uncorrelated variables, the principal 
components, which were combinations of the original 
cognitive measures, and explain as much of the variance 
in the original variables as possible in a more compact 
and insightful form. The ﬁ rst four principal components, 
which can be described as representing Logical Memory 
opposed to Complex Figure (PC1), Spatial Span and Digit 
Span (PC2), Auditory Verbal Memory and Complex 
Figure (PC3), and Digit Span opposed to Complex Figure 
and Spatial Span (PC4), explained almost 53% of the total 
variation in the data, the proportion of variance explained 
being 16·1% for the ﬁ rst component down to 10·1% for 
the fourth component. We tested if there was a diﬀ erence 
between treatment groups for these four factors and 
noted no signiﬁ cant diﬀ erence (webtable 1)
Group comparisons do not identify impairment in 
subgroups of the population or account for practice eﬀ ects. 
To assess performance of individual women, we used the 
RCI with a correction for observed practice eﬀ ects on each 
measure.16 Few women showed a reliable decline on three 
or more tasks at 6 months (3 anastrozole, 3 placebo) or at 
24 months (2 anastrozole, 2 placebo), and there were no 
signiﬁ cant diﬀ erences between the groups (webtable 2). 
There were no diﬀ erences between groups in the 
proportions of women experiencing psychological distress 
as measured by the GHQ12 at each timepoint (table 3). 
Both groups had similar scores on the CFQ questionnaire 
at baseline, 6 months, and 24 months (data not shown). 
The baseline GHQ12 score signiﬁ cantly correlated with 
the CFQ score (z=–2·748, p=0·006, Wilcoxon rank-sum 
test), data not shown. The women who were anxious 
reported more lapses in attention in everyday life (data not 
shown).
Few women complained of changes in their attention 
and memory at 6 months or 24 months, and there were 
no diﬀ erences between the treatment groups (table 2). 
141 women were also interviewed about their adherence 
to taking medication at the 24-month assessment. 70 of 
141 (50%) reported forgetting to take their tablets during 
the study period (31 anastrozole, 39 placebo), but most 
(53 of 70; 76%) “rarely” forgot. Only 8 of 141 (6%) patients 
reported occasions where they had chosen not to take the 
trial medication (4 anastrozole, 4 placebo). 
Non-adherence was reported for the women who missed 
more than 10% of their tablets or did not take their tablets 
for an unknown duration. Clinicians or research nurses 
suggested drug holidays (ie, temporary cessation of trial 
medication) for some women who experienced marked 
side-eﬀ ects during the study period. Drug holidays for 
patients were quite rare. By the 6-month assessment, ﬁ ve 
women in the anastrozole and one woman in the placebo 
group had been told to take a drug holiday (table 2). The 
duration of non-adherence is unknown for 3 women in 
the anastrozole group and one woman in the placebo 
group. The two other women in the anastrozole group 
missed more than 10% of their tablets. From 6 months to 
24 months, one woman in the anastrozole group did not 
take her tablets for an unknown duration.
Women also self-initiated drug holidays; by 6 months, 
four women in the anastrozole and three in the placebo 
groups reported taking a drug holiday. The details of non-
adherence are unknown for these women. From 6 months 
to 24 months, three women in the anastrozole group and 
one woman in the placebo group self-initiated drug 
holidays (table 2). The duration of non-adherence was 
unknown for the woman in the placebo group and 
two women in the anastrozole group. The other woman 
in the anastrozole group missed more than 10% of her 
tablets. The main analysis was also done without these 
patients and there was no diﬀ erence in the ﬁ ndings 
(webtable 3).
There was no signiﬁ cant eﬀ ect of time or treatment 
group on the total Endocrine Symptom score (data not 
shown). To assess changes in individual endocrine 
symptoms from baseline, responses were dichotomised 
into those who reported, “somewhat, a little bit, not at all” 
or “quite a bit or very much”. The only endocrine 
symptom that showed a change over time was hot 
ﬂ ushes, where signiﬁ cantly more women in the 
anastrozole group experienced “quite a bit or very much” 
Mean change from baseline (SE) Diﬀ erence between 








Immediate recall –0·06 (0·12) –0·08 (0·16) –0·04 (0·17) –0·04 (–0·51 to 0·43)
Total recall 1–5 0·85 (0·51) 0·89 (0·74) 0·80 (0·71) 0·09 (–1·94 to 2·12)
Delayed recall 7 0·25 (0·18) 0·33 (0·26) 0·15 (0·24) 0·18 (–0·52 to 0·89)
Logical memory
Immediate recall 0·26 (0·27) 0·08 (0·36) 0·46 (0·41) –0·38 (–1·46 to 0·70)
Delayed recall 0·22 (0·27) 0·17 (0·37) 0·27 (0·38) –0·10 (–1·15 to 0·95)
Complex ﬁ gure
Immediate recall 1·24 (0·36) 1·45 (0·55) 1·02 (0·47) 0·43 (–1·01 to 1·87)
Delayed recall 1·33 (0·33) 1·51 (0·46) 1·16 (0·46) 0·35 (–0·94 to 1·64)
Letter cancellation
Eﬃ  ciency 0·69 (0·36) 0·54 (0·48) 0·83 (0·53) –0·29 (–1·70 to 1·12)
Letter number sequencing –0·44 (0·15) –0·40 (0·22) –0·47 (0·22) 0·07 (–0·55 to 0·68)
Spatial span
Forwards –0·14 (0·12) –0·08 (0·14) –0·20 (0·19) 0·12 (–0·34 to 0·58)
Backwards –0·02 (0·09) 0·05 (0·12) –0·09 (0·13) 0·14 (–0·21 to 0·49)
Total –0·20 (0·15) –0·11 (0·18) –0·30 (0·24) 0·19 (–0·41 to 0·78)
Digit span
Forwards –0·02 (0·11) 0·08 (0·16) –0·14 (0·15) 0·22(–0·22 to 0·66)
Backwards –0·48 (0·12) –0·63 (0·17) –0·33 (0·18) –0·30 (–0·80 to 0·19)
Total –0·42 (0·18) –0·46 (0·25) –0·39 (0·25) –0·07 (–0·77 to 0·63)
Executive function
Stroop 0·34 (0·36) 0·37 (0·58) 0·30 (0·44) 0·07 (–1·37 to 1·51)
Total verbal ﬂ uency –0·01 (0·56) –0·24 (0·85) 0·23 (0·74) –0·48 (–2·71 to 1·75)
Table 4: Mean change from baseline of each task for all 207 participants in the main analysis, by 
treatment group and diﬀ erence of the mean change between groups across study time points
See Online for webtables 1–3
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hot ﬂ ushes at 24 months (23 of 76 [30%] vs 11 of 73 [15%], 
p=0·032, not corrected for multiple comparison).
Discussion
The ﬁ ndings from this comprehensive, prospective 
neuropsychological study show that anastrozole does not 
seem to impair any aspect of cognitive function in 
postmenopausal women at increased lifetime risk of 
breast cancer who were participating in a placebo-
controlled trial. Performance did not diﬀ er between or 
within treatment groups across time; scores on the 
objective tasks were within the normal ranges for women 
of this age. Additionally, assessment of individual change 
in scores by use of the RCI was similar for both groups. 
The strength of this study is that it is part of a large 
double-blind randomised clinical trial, which provides a 
better assessment of putative cognitive impairment than 
previous cross-sectional or observational cognitive 
studies. As this was a double-blind study, we can be 
conﬁ dent that any noted diﬀ erences in cognitive 
performance are true and not aﬀ ected by women knowing 
which treatment they were receiving. The weakness is 
that the study sample was relatively small compared with 
therapeutic trials (n=227), and by 24 months attrition 
might have caused a loss of power to detect changes. 
However, this sample was much larger than those in 
other published neuropsychological studies involving 
women with breast cancer. The largest published sample 
sizes to date in prospective studies with pre-treatment 
assessments were of 10918 and 101.19 
Self-reporting of cognitive impairment by participants 
in this IBIS II study was much lower than that reported 
by patients with breast cancer receiving endocrine or 
chemotherapy treatments. At 6 months, only 13 of 
101 (13%) women receiving anastrozole in the IBIS II 
study complained of memory problems. This proportion 
was much lower than that reported in a prospective study 
of women with breast cancer who received endocrine 
treatment with or without chemotherapy.20 77 of 93 (83%) 
of those who received both treatments complained of 
memory prob lems at 6 months compared with 24 of 
49 (49%) who received endocrine treatment only. It is 
well documented that self-reported cognitive problems 
are associated with high levels of anxiety, but this cannot 
explain the diﬀ erence because similar proportions of 
women scored above threshold on the GHQ12 in both 
studies. One suggestion is that some women who have 
breast cancer experience post-traumatic stress disorders.21 
A diagnosis of breast cancer plus ensuing treatment 
interrupts normal life and might sensitise patients to 
make inaccurate objective judgments about the way they 
function cognitively before and after diagnosis.
Our ﬁ ndings lend support to the view that depletion of 
oestradiol concentrations once a woman is post-
menopausal does not notably interfere with the processes 
of memory and attention over a 24-month period. The 
eﬀ ect of the recommended longer-term use (5 years) of 
anastrozole is still unknown, but most of the detrimental 
side-eﬀ ects, such as vasomotor complaints, sexual 
dysfunction, arthralgia, myalgia, and bone loss, occur 
during the ﬁ rst year of treatment.22 However, there is no 
evidence available for us to state unequivocally that 
cognition will not be aﬀ ected in the long term, nor can 
we postulate what the eﬀ ects might be for women who 
receive both aromatase inhibitors and chemotherapy as 
treatments for breast cancer. Data from two studies9,23 
suggest that women who receive both chemotherapy and 
endocrine treatment (tamoxifen) are compromised more 
than those receiving either treatment alone. 
Although our ﬁ ndings conﬂ ict with other published 
work,8,9,23 they are similar to data reported in clinical trials 
of raloxifene, a benzothiophene member of the selective 
oestrogen-receptor-modulator class of compounds used 
in the treatment and prevention of osteoporosis. The 
Multiple Outcomes of Raloxifene study (MORE)24 was a 
randomised clinical trial of raloxifene (60 mg or 120 mg) 
versus placebo in 7478 postmenopausal women. Although 
there was a tendency towards a decline in performance 
on verbal memory and attention tasks, there were no 
signiﬁ cant diﬀ erences between the three groups at 
baseline or after 3 years.24
Mean change from baseline (SE) Diﬀ erence between 








Immediate recall –0·05 (0·14) –0·03 (0·19) –0·14 (0·20) –0·17 (–0·39 to 0·72)
Total recall 1–5 0·83 (0·57) 1·20 (0·84) 0·44 (0·79) 0·75 (–1·51 to 23·02)
Delayed recall 7 0·36 (0·19) 0·43 (0·28) 0·29 (0·25) 0·14 (–0·60 to 0·89)
Logical memory
Immediate recall 0·46 (0·35) 0·16 (0·47) 0·77 (0·51) –0·61 (–1·98 to 0·75)
Delayed recall 0·38 (0·33) 0·37 (0·44) 0·39 (0·50) –0·02 (–1·33 to 1·29)
Complex ﬁ gure
Immediate recall 0·81 (0·44) 1·08 (0·66) 0·53 (0·58) 0·55 (–1·19 to 2·29)
Delayed recall 0·92 (0·41) 1·15 (0·58) 0·68 (0·57) 0·47 (–1·14 to 2·09)
Letter cancellation
Eﬃ  ciency 1·10 (0·39) 0·74 (0·53) 1·48 (0·58) –0·74 (–2·29 to 0·80)
Letter number sequencing –0·28 (0·17) –0·30 (0·25) –0·27 (0·25) 0·02 (–0·72 to 0·67)
Spatial span
Forwards –0·15 (0·13) –0·08 (0·16) –0·23 (0·20) 0·15 (–0·35 to 0·66)
Backwards –0·04 (0·10) 0·12 (0·14) –0·04 (0·15) 0·16 (–0·24 to 0·57)
Total –0·15 (0·17) –0·03 (0·21) –0·27 (0·25) 0·24 (–0·41 to 0·90)
Digit span
Forwards –0·13 (0·13) 0·35 (0·19) –0·10 (0·17) 0·45 (–0·05 to 0·95)
Backwards –0·38 (0·14) –0·43 (0·19) –0·33 (0·20) –0·10 (–0·64 to 0·44)
Total –0·14 (0·20) –0·06 (0·30) –0·35 (0·27) –0·41 (–0·40 to 1·22)
Executive function
Stroop 0·35 (0·40) 0·32 (0·66) 0·38 (0·45) –0·06 (–1·65 to 1·53)
Total verbal ﬂ uency 0·44 (0·61) 0·35 (0·94) 0·55 (0·78) –0·20 (–2·63 to 2·22)
Table 5: Mean change between 6 months and baseline of each task for all 207 participants in the main 
analysis, by treatment group and diﬀ erence of the mean change between the groups
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Most previous HRT users participating in the IBIS II 
cognitive study (85 of 114 [75%]) had stopped taking HRT 
12 months before starting the study. However, there was a 
signiﬁ cant diﬀ erence in cognitive performance at the 
baseline assessment between women who had previously 
taken HRT and those who had not. Performance was 
poorer for previous HRT users on tasks requiring 
sustained attention and verbal memory, ie, logical memory 
immediate, logical memory delayed, letter number 
sequencing, and on a task of executive function. These 
ﬁ ndings are interesting in the light of the data from the 
Women’s Health Initiative Memory Study (WHIMS),25 
which suggested that use of HRT is detrimental in the 
older postmenopausal woman. The WHIMS trial was 
discontinued prematurely because of the increased risk of 
stroke, heart disease, breast cancer, and pulmonary 
embolism. The neuropsychological test ﬁ ndings showed 
those women who received oestrogen treatment (alone or 
combined with progesterone) had a higher risk of cognitive 
decline and probable dementia compared with those who 
received placebo.25,26 The mean age of the WHIMS 
participants was 72 years and researchers concluded that 
HRT initiated in women over 65 years of age might 
increase risk for non-speciﬁ c dementia through cerebral 
vascular events.27 It should be noted, however, that the 
mean age of the IBIS II participants was 57 years. 
The endocrine symptom proﬁ le for both groups in the 
IBIS II cognitive study was similar over time. We know 
that from other work in an adjuvant setting that most 
side-eﬀ ects of endocrine treatments tend to develop 
within the ﬁ rst 3 months and thereafter plateau or 
improve. The only substantial diﬀ erence, noted at 
24 months, was a sustained increase in hot ﬂ ushes for the 
women taking anastrozole. Complaints of arthralgia were 
not diﬀ erent between the groups with 26 of 100 (26%) 
women in the anastrozole group and 30 of 106 (28%) of 
those in the placebo group reporting this symptom as 
“quite a bit or very much” at 6 months. Although 
surprising, the endocrine symptom proﬁ le resembles 
those from an earlier chemoprevention study of tamoxifen 
versus placebo, where the only signiﬁ cant diﬀ erence 
between groups was for vasomotor complaints.28 Patient-
reported outcomes from standard ised assessments are 
reliable and several published studies have shown that 
they represent better the side-eﬀ ects of drugs than those 
reported by clinicians on case report forms.29  
Poor adherence merits further study for the low reporting 
of menopausal-type symptoms, but self-rated and clinician-
reported adherence was better than that in previous 
chemoprevention studies. For example in the Royal 
Marsden Hospital tamoxifen randomised chemo-
prevention trial (TAMOPLAC) and the IBIS I studies, 
about 38% (153/401) of the psychosocial study participants 
stopped taking the tablets before the end of the 5-year trial 
or took them infrequently.28 Another possible explanation 
for few symptoms is that more women in the anastrozole 
group self-initiated drug holidays, especially by the 
24-month assessment, which might have decreased the 
likelihood of detecting cognitive impairments.  
The current study does not provide clear evidence 
that anastrozole, compared with placebo, produced 
cognitive impairments over a 24-month period. 
However, the longer-term eﬀ ects, alone or after 
chemotherapy treatment, are unknown. These ﬁ ndings 
should be reassuring in the short term for post-
menopausal women being treated with anastrozole, 
their clinicians, and carers. At present, cognitive 
research in this area is restricted by methodological 
challenges and the absence of standardisation in 
neuropsychological studies. An international task force 
has been proposed to provide guidelines for future 
research to address these issues.30
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